Transporter-mediated natural product-drug interactions for the treatment of cardiovascular diseases

Weibin Zha*

MyoKardia, South San Francisco, CA, USA

The growing use of natural products in cardiovascular (CV) patients has been greatly raising the concerns about potential natural producteCV drug interactions. Some of these may lead to unexpected cardiovascular adverse effects and it is, therefore, essential to identify or predict potential natural producteCV drug interactions, and to understand the underlying mechanisms. Drug transporters are important determinants for the pharmacokinetics of drugs and alterations of drug transport has been recognized as one of the major causes of natural productedrug interactions. In last two decades, many CV drugs (e.g., angiotensin II receptor blockers, beta-blockers and statins) have been identified to be substrates and inhibitors of the solute carrier (SLC) transporters and the ATP-binding cassette (ABC) transporters, which are two major transporter superfamilies. Meanwhile, in vitro and in vivo studies indicate that a growing number of natural products showed cardioprotective effects (e.g., gingko biloba, danshen and their active ingredients) are also substrates and inhibitors of drug transporters. Thus, to understand transporter-mediated natural producteCV drug interactions is important and some transporter-mediated interactions have already shown to have clinical relevance. In this review, we review the current knowledge on the role of ABC and SLC transporters in CV therapy, as well as transporter modulation by natural products used in CV diseases and their induced natural producteCV drug interactions through alterations of drug transport. We hope our review will aid in a comprehensive summary of transporter-mediated natural producteCV drug interactions and help public and physicians understand these type of interactions.

Keywords: Cardiovascular drugs, Natural products, Drug transporters, Natural productedrug interaction Pharmacokinetics